Jae-Joon Kim

Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Fenwick & West LLP provides legal services to technology and life sciences clients. Its practice areas include antitrust and unfair competition, appellate, complex business litigation, copyright, corporate and securities, employment and labor, executive compensation and benefits, intellectual property, and IP litigation. The firm offers legal advisory services in areas such as mergers and acquisitions, patent prosecution, privacy and information security. The company was founded in 1972 and is headquartered in Mountain View, CA.

EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA.

Mirae Asset Capital Co., Ltd. (Mirae Asset Capital) is a private equity and venture capital firm founded in 1997. The firm is headquartered in Seoul, South Korea.

Mirae Asset Securities Co., Ltd. (Broker) (Mirae Asset-Broker) is the broker/dealer division of Mirae Asset Securities Co., Ltd. (KRX: 006800), a publicly-listed investment banking and stock brokerage company headquartered in Seoul, South Korea. Founded in 1902, Mirae Asset-Broker originates, structures, and executes a series of products and solutions linked to equity, derivatives, commodities, options, fixed-income, currency, and alternative investment products and provides them to financial institutions and wealth management organizations in Korea and overseas.

Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea.

Kyung Hee University provides academic courses and grants academic degrees. It has udergraduate, graduate, international student, and international faculty programs. The firm also provides scholarships and operates Kyung Hee Medical Center, Kyung Hee University Hospital at Gangdong, and Kangnam Korean Hospital. The company was founded on February 15, 1949 and is headquartered in Seoul, South Korea.

Rutter Associates Korea (Rutter PE) is an independent private equity firm headquartered in Seoul, Korea. The firm is established in 2004.

EQ Partners Co., Ltd. (Ecu Partners) is a private equity subsidiary of Korea Investment Holdings Co. headquartered in Seoul, South Korea. The firm was founded in 2010.

Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014.

Health Prime International LLC engages in the supply of outsourced medical billing services. It offers PrimeEHR, PrimeQuality, PrimeTranscription, PrimeContact, PrimeConsult, PrimeSmartCharge, and PrimeMarketing. The company was founded by Vinod K. Shah in 2004 and is headquartered in National Harbor, MD.

Midas Dong-A Investment Co Ltd (Midas Dong-A) is a venture capital firm headquartered in Seoul, Korea. The firm is established in 2013 by Midas Dong-A Co Ltd for its investment activities.

Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA.

Triumvira Immunologics, Inc. develops and manufactures pharmaceutical products. The company was founded by Jonathan Bramson in 2015 and is headquartered in Hamilton, Canada.

Alliance for Clinical Research Excellence & Safety is a non-governmental organization that builds, implements, and maintains comprehensive systems. The non-profit company is based in Cambridge, MA. The company was founded by Greg Koski.

Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA.

Triumvira Immunologics USA, Inc. develops and manufactures novel T cell therapies for cancer. The company is based in Austin, TX and has subsidiaries in Canada. Paul Lammers has been the CEO of the company since 2018.

MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts.

Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation.

Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer.